Global Rituximab Biosimilars Market Report 2023: Major Players Include Pfizer, Mylan, Amgen, Teva Pharmaceutical Industries And Celltrion Healthcare

Dublin /PRNewswire/ - The "Rituximab Biosimilars Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.

This report provides strategists, marketers and senior management with the critical information they need to assess the market.

The global rituximab biosimilars market is expected to grow from $1.77 billion in 2021 to $2.05 billion in 2022 at a compound annual growth rate (CAGR) of 16.1%. The rituximab biosimilars market is expected to reach $3.42 billion in 2026 at a CAGR of 13.6%.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis

Major players in the rituximab biosimilars market are Pfizer Inc., Mylan Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Celltrion Healthcare Co. Ltd., Sandoz International GmbH, Reliance Life Sciences, C.H. Boehringer Sohn AG & Ko. KG, BioXpress Therapeutics SA, and Intas Biopharmaceuticals Ltd.

The rituximab biosimilar market consists of sales of mabthera, truxima, ruxience or rixathon. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Rituximab biosimilar refers to a chimeric monoclonal antibody that is directed against the immune system B cell-specific protein CD20. Rituximab kills B cells, making it useful for treating conditions where there are too many, too active, or otherwise abnormal B cells.

North America was the largest region in the rituximab biosimilars market in 2022. Middle East is expected to be the fargest growing region in the forecast period. The regions covered in the rituximab biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The main routes of administration in rituximab biosimilar are subcutaneous, intravenous, and molecular types. Intravenous therapy is a medical procedure in which fluids, drugs, and nutrients are delivered straight into a patient's vein. The different applications include non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and others and are distributed through various channels such as hospital pharmacy, online pharmacy, retail pharmacy, and other direct distribution channels.

The rising prevalence of non-Hodgkin's lymphoma (NHL) is predicted to contribute to the growth of the rituximab biosimilars market. Non-Hodgkin's lymphoma or lymphoma is cancer that starts in white blood cells, and lymphocytes that are part of the body's immune system. According to the American Cancer Society, NHL is the most common cancer in the USA accounting for about 4% of all cancers. About 81,560 people (45,630 males and 35,930 females) are diagnosed with NHL in 2021 in the USA. Thus, growing cases of non-Hodgkin's lymphoma are predicted to generate high demand for rituximab biosimilars over the forecast period.

The high cost associated with rituximab biosimilars acts as a major restraint for the growth of rituximab's market over the upcoming years. The cost of the subcutaneous option was costlier than IV biosimilar rituximab. The cost of subcutaneous formulation for patients with small body size is between $3,805 and $8,807 and for medium body size between $325 to $6109 and $484 to $6267 for 2 infusion speeds. The high costs of rituximab biosimilars make it unaffordable for the treatment of patients with low income, hindering the growth of the market.

The companies operating in the biosimilars are continuously focusing on new product development in collaborations with other companies operating in the industry. Innovations through partnerships are shaping the rituximab biosimilars market. For instance, in May 2020, Teva Pharmaceutical Industries Ltd. and Celltrion Healthcare Co. Ltd together announced the launch of biosimilar Truxima (rituximab-abbs) injection in the USA for the treatment of polyangiitis and rheumatoid arthritis. Truxima is the only biosimilar to Roche's Rituxan (rituximab) available in the USA for the treatment of rheumatoid arthritis.

The countries covered in the rituximab biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Key Topics Covered:

1. Executive Summary

2. Rituximab Biosimilars Market Characteristics

3. Rituximab Biosimilars Market Trends And Strategies

4. Rituximab Biosimilars Market - Macro Economic Scenario
4.1 COVID-19 Impact On Rituximab Biosimilars Market
4.2 Ukraine-Russia War Impact On Rituximab Biosimilars Market
4.3 Impact Of High Inflation On Rituximab Biosimilars Market

5. Rituximab Biosimilars Market Size And Growth
5.1. Global Rituximab Biosimilars Historic Market, 2017-2022, $ Billion
5.1.1. Drivers Of The Market
5.1.2. Restraints On The Market
5.2. Global Rituximab Biosimilars Forecast Market, 2022-2027F, 2032F, $ Billion
5.2.1. Drivers Of The Market
5.2.2. Restraints On the Market

6. Rituximab Biosimilars Market Segmentation
6.1. Global Rituximab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

• Non-Hodgkin's lymphoma
• Chronic Lymhocytic Leukemia
• Rheumatoid arthritis
• Other Applications

6.2. Global Rituximab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
• Other Direct Distribution Channels

6.3. Global Rituximab Biosimilars Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

• Subcutaneous
• Intravenous
• Molecular Type

7. Rituximab Biosimilars Market Regional And Country Analysis
7.1. Global Rituximab Biosimilars Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
7.2. Global Rituximab Biosimilars Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

For more information about this report visit https://www.researchandmarkets.com/r/xmn7r3

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.